Brugge Joan, Hung Mien-Chie, Mills Gordon B
Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Cancer Cell. 2007 Aug;12(2):104-7. doi: 10.1016/j.ccr.2007.07.014.
Although multiple members of the phosphatidylinositol-3-kinase pathway (PI3K) are targeted by germline or somatic mutations, functional mutations in the three akt isoforms have proven elusive. This is somewhat surprising, as AKT represents a key node in the PI3K pathway, exhibiting transforming activity when incorporated into the AKT8 retrovirus. A recent report in Nature identifies a transforming E17K PH domain mutation in akt1 in breast (8%), colorectal (6%), and ovarian (2%) cancers. E17K-akt1 transforming activity appears due to PtdIns(3,4)P2- and PtdIns(3,4,5)P3-independent recruitment of AKT1 to the membrane. This novel observation raises important theoretical and clinical questions.
尽管磷脂酰肌醇-3-激酶通路(PI3K)的多个成员会受到种系或体细胞突变的影响,但三种Akt亚型的功能突变却难以捉摸。这有点令人惊讶,因为AKT是PI3K通路中的关键节点,当整合到AKT8逆转录病毒中时具有转化活性。《自然》杂志最近的一篇报道发现,在乳腺癌(8%)、结直肠癌(6%)和卵巢癌(2%)中,akt1存在一种具有转化作用的E17K PH结构域突变。E17K-akt1的转化活性似乎是由于AKT1不依赖磷脂酰肌醇(3,4)二磷酸(PtdIns(3,4)P2)和磷脂酰肌醇(3,4,5)三磷酸(PtdIns(3,4,5)P3)而被招募到细胞膜上。这一新发现提出了重要的理论和临床问题。